David A. Siegel Sio Gene Therapies Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.25 - $0.73 $13,959 - $40,761	-55,838 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.55 - $1.47 $8,470 - $22,638	-15,400 Reduced 21.62%	55,838 $37,000
Q4 2021 Feb 14, 2022	SELL	$1.29 - $2.36 $22,656 - $41,448	-17,563 Reduced 19.78%	71,238 $92,000
Q3 2021 Nov 15, 2021	SELL	$1.81 - $2.7 $386,073 - $575,910	-213,300 Reduced 70.61%	88,801 $193,000
Q2 2021 Aug 16, 2021	SELL	$2.07 - $2.89 $44,091 - $61,557	-21,300 Reduced 6.59%	302,101 $825,000

Q1 2021 May 17, 2021	BUY	$2.34 - $3.44 $756,758 - $1.11 Million	323,401 New	323,401 $844,000

147K

Ticker SIOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,975,200
Description
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.